These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 24744045

  • 1. Early and delayed prediction of axillary lymph node neoadjuvant response by (18)F-FDG PET/CT in patients with locally advanced breast cancer.
    García Vicente AM, Soriano Castrejón Á, León Martín A, Relea Calatayud F, Muñoz Sánchez Mdel M, Cruz Mora MÁ, Jiménez Londoño GA, Espinosa Aunión R.
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1309-18. PubMed ID: 24744045
    [Abstract] [Full Text] [Related]

  • 2. Prognostic Role of Early and End-of-Neoadjuvant Treatment 18F-FDG PET/CT in Patients With Breast Cancer.
    García Vicente AM, Amo-Salas M, Relea Calatayud F, Muñoz Sánchez Mdel M, Pena Pardo FJ, Jiménez Londoño GA, Álvarez Cabellos R, Espinosa Aunión R, Soriano Castrejón Á.
    Clin Nucl Med; 2016 Jul; 41(7):e313-22. PubMed ID: 26953659
    [Abstract] [Full Text] [Related]

  • 3. Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.
    Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):32-40. PubMed ID: 23929431
    [Abstract] [Full Text] [Related]

  • 4. Subtype-Guided 18 F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study.
    Wu S, Wang Y, Li J, Zhang N, Mo M, Klimberg S, Kaklamani V, Cochet A, Shao Z, Cheng J, Liu G.
    Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
    [Abstract] [Full Text] [Related]

  • 5. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
    García Vicente AM, Soriano Castrejón A, Cruz Mora MÁ, Ortega Ruiperez C, Espinosa Aunión R, León Martín A, González Ageitos A, Van Gómez López O.
    Rev Esp Med Nucl Imagen Mol; 2014 Apr; 33(1):1-5. PubMed ID: 23707190
    [Abstract] [Full Text] [Related]

  • 6. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J, Wang Y, Mo M, Bao X, Zhang Y, Liu G, Zhang J, Geng D.
    Oncotarget; 2015 Oct 06; 6(30):29388-95. PubMed ID: 26336821
    [Abstract] [Full Text] [Related]

  • 7. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
    Dalus K, Reitsamer R, Holzmannhofer J, Rendl G, Pirich C, Kronberger C, Rettenbacher L.
    Nuklearmedizin; 2011 Oct 06; 50(1):33-8. PubMed ID: 21336417
    [Abstract] [Full Text] [Related]

  • 8. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
    Koolen BB, Valdés Olmos RA, Elkhuizen PH, Vogel WV, Vrancken Peeters MJ, Rodenhuis S, Rutgers EJ.
    Breast Cancer Res Treat; 2012 Aug 06; 135(1):231-40. PubMed ID: 22872522
    [Abstract] [Full Text] [Related]

  • 9. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
    Koolen BB, Valdés Olmos RA, Wesseling J, Vogel WV, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Vrancken Peeters MJ.
    Ann Surg Oncol; 2013 Jul 06; 20(7):2227-35. PubMed ID: 23456316
    [Abstract] [Full Text] [Related]

  • 10. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N, Kadioglu H, Yildiz S, Yucel SB, Gucin Z, Erdogan EB, Aydin M, Muslumanoglu M.
    Acta Radiol; 2015 Aug 06; 56(8):917-23. PubMed ID: 25013091
    [Abstract] [Full Text] [Related]

  • 11. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients.
    Straver ME, Aukema TS, Olmos RA, Rutgers EJ, Gilhuijs KG, Schot ME, Vogel WV, Peeters MJ.
    Eur J Nucl Med Mol Imaging; 2010 Jun 06; 37(6):1069-76. PubMed ID: 20130860
    [Abstract] [Full Text] [Related]

  • 12. FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.
    Rousseau C, Devillers A, Campone M, Campion L, Ferrer L, Sagan C, Ricaud M, Bridji B, Kraeber-Bodéré F.
    Eur J Nucl Med Mol Imaging; 2011 Jun 06; 38(6):1029-36. PubMed ID: 21308372
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.
    Riegger C, Koeninger A, Hartung V, Otterbach F, Kimmig R, Forsting M, Bockisch A, Antoch G, Heusner TA.
    Acta Radiol; 2012 Dec 01; 53(10):1092-8. PubMed ID: 23002144
    [Abstract] [Full Text] [Related]

  • 14. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
    Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, Park IA, Noh DY, Chung JK, Bang YJ.
    Breast Cancer; 2013 Apr 01; 20(2):167-73. PubMed ID: 22311581
    [Abstract] [Full Text] [Related]

  • 15. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L, Cervino AR, Michieletto S, Saibene T, Orvieto E, Bozza F, Ghiotto C.
    Q J Nucl Med Mol Imaging; 2017 Jun 01; 61(2):205-215. PubMed ID: 25501326
    [Abstract] [Full Text] [Related]

  • 16. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
    Machida Y, Kubota K, Katayama T, Toriihara A, Shibuya H.
    Eur J Surg Oncol; 2013 Jan 01; 39(1):26-30. PubMed ID: 23122913
    [Abstract] [Full Text] [Related]

  • 17. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
    Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N, Kondo T, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H.
    BMC Cancer; 2008 Jun 09; 8():165. PubMed ID: 18541009
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
    Hahn S, Hecktor J, Grabellus F, Hartung V, Pöppel T, Kimmig R, Forsting M, Antoch G, Heusner TA.
    Acta Radiol; 2012 Jun 01; 53(5):518-23. PubMed ID: 22547387
    [Abstract] [Full Text] [Related]

  • 19. Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience.
    Kim J, Lee J, Chang E, Kim S, Suh K, Sul J, Song I, Kim Y, Lee C.
    World J Surg; 2009 May 01; 33(5):943-9. PubMed ID: 19259728
    [Abstract] [Full Text] [Related]

  • 20. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
    Andrade WP, Lima EN, Osório CA, do Socorro Maciel M, Baiocchi G, Bitencourt AG, Fanelli MF, Damascena AS, Soares FA.
    Eur J Surg Oncol; 2013 Dec 01; 39(12):1358-63. PubMed ID: 24120422
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.